On behalf of Genentech, I respectfully request the NCCN Lung Cancer Guideline Panel to review the enclosed data for Tarceva® (erlotinib) monotherapy in the maintenance treatment of non-small cell lung cancer (NSCLC).

Specific Changes: Consider updating the NCCN Guidelines with the final results from the Phase III SATURN trial.1

FDA Clearance: FDA has approved Tarceva monotherapy for the maintenance treatment of patients with locally advanced or metastatic NSCLC whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. Please refer to the enclosed prescribing information for the full FDA-approved indications and safety information.

Rationale: Final results from the SATURN trial were recently published by Lancet Oncology on June 1, 2010.1 The SATURN trial is the pivotal study supporting the FDA-approved indication of Tarceva monotherapy in the maintenance treatment of NSCLC.1-3

The following enclosures are included for your review (copyright-paid where applicable):

- Tarceva Prescribing Information

Cited References


